Who's Who in 2015: Exploring the Exciting BioPharma Venture Ride
Speaker: Jonathan Norris | Managing Director, Silicon Valley Bank
Date/Time: Wednesday, December 2nd, 8:00-10:00 AM, presentation begins at 8:30 sharp
Place: Johnson & Johnson Innovation, JLABS
329 Oyster Point Blvd – 3rd Floor
South San Francisco, CA
Pricing: $12 | General Public
$8 | Student/Academic
$25 | Onsite
Jon Norris is a managing director for SVB's Healthcare practice. Norris oversees business development efforts for banking and lending opportunities as well as spearheading strategic relationships with many healthcare venture capital firms. He also helps SVB Capital through sourcing and advising on direct equity co-investment and limited partnership allocations. In addition, he has authored numerous thought leadership pieces examining the flow of capital into healthcare, including detailed analysis of venture-backed M&A and IPOs. Norris has more than thirteen years of banking experience working with life science companies and venture capital firms. Prior to joining SVB Capital, Norris was a founding member and senior vice president of Square 1 Bank, an early stage technology bank, where he was responsible for sourcing deals and managing regional and national venture capital relationships. Norris also served more than six years at Imperial Bank (subsequently acquired by Comerica Bank), most recently as senior vice president and group manager of the Northern California Life Science Practice. Prior to banking, Norris was a practicing litigation attorney, specializing in employment defense and toxic tort litigation. Norris earned a bachelor's degree in business administration from the University of California, Riverside and a juris doctorate from Santa Clara University.
About John: Norris spends most of his non-banking time with his family in Los Altos, attending and coaching many youth sports. An avid baseball fan, he still plays baseball in a men's baseball league in San Jose.
2015 has been a wild ride, but how does it compare to 2013 and 2014? What does it take to go IPO and when are acquirers engaging in M&A? This presentation will explore the current state of the BioPharma venture world and include the following topics:
• What does it take to go IPO and when are acquirers engaging in M&A?
• Explore current equity financings vs. the last three years
• Analysis of which venture firms are most active
• The crossover phenomenon and what does it mean for your company?
- Which crossovers are investing and at which stage
- Step-up in private equity rounds
- IPO pre-money valuation and IPO success
• Exits: the trend to early stage M&A in Biopharma, and explore time to exit, up front and all-in values, and multiples on capital invested by indication.
- Types of IPOs completed since 2013 and changes in 2015 to date
- Average dollars raised and pre money by indication.
At the end of this talk you should be informed as to who is investing in BioPharma and comps for M&A and IPO in your indication.